
# ðŸ§ª Suggested Input Combinations

Here are a few diverse Drug-Target pairs to test the prediction model.
You can **copy and paste** these directly into the Streamlit app.

*(Note: Since the current model is trained on synthetic data for demonstration, predicted values will be random, but the pipeline is fully functional.)*

## 1. Lapatinib + EGFR
**Description**: Lapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and EGFR pathways. It is used in breast cancer and other solid tumors.

**Drug (SMILES)**:
```text
CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F
```

**Target (EGFR Sequence)**:
```text
MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA
```

---

## 2. Aspirin + COX-1
**Description**: Aspirin is a common NSAID that irreversibly inhibits COX-1, reducing prostaglandin production to relieve pain and inflammation.

**Drug (SMILES)**:
```text
O=C(C)Oc1ccccc1C(=O)O
```

**Target (COX-1 Sequence - Human)**:
```text
MSRSLLLRFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTRTGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRSNLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRFLLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQYQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLYATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKFDPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEALVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQELVGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICSPEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL
```

---

## 3. Imatinib + KIT
**Description**: While famous for targeting BCR-ABL, Imatinib is also a potent inhibitor of c-KIT, a receptor tyrosine kinase often mutated in Gastrointestinal Stromal Tumors (GIST).

**Drug (SMILES)**:
```text
Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C
```

**Target (KIT Sequence - Human)**:
```text
MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSHPVTFSCYGDKPAIQWLADGPLFPGPGPVDNQLSILPNPAQVYWKKFLGKPMVEVKDSGAYTCVENELSGTRATEQTVQVRAASVPSAVIVISPPEDHPWTVGSPFAYCNSTDCFPSDQIYKTGTYWKEATDSDTEKSNYYCNTRWIFPPVAAVRESIRHSSQIVLANAFSVSSFVPMSLMVYRAPQVSLCKESWTESKKEIFWKQLHRSYNSDLQYRKVNKAWSTDISFSPKPTNAMFSCLATNALGSQEITSVIQIEVKPSPFLELEKVNETYMKMACNETRAGITNLNWDQLPSHSNQINKSVIKNKSTAYTLVSQGSLVSDKVTERYVLQGTTVGDLQYIHSPDFILVGAGGEKSLISLTFAVEKYSEAGQEITWTRNSSEDKIIILGANATYKEIHGNNSVYLCNNNIHGSTHESLVQLEIAAPQYPLTDHVSSAGIFVPFIVTLLVLVGIIYIIRRKLFEIKNFSMLSIYHLSDASDSDGSADTVSTISNPEEDSEAIQADTKISPGIDGMVTGNKPEEIEKVLVAYVSKGMLDEKLFGEGTYGTVFKGMLHPRGNQIGAVKVLKAMPKKEIEKYTVPMLKIGLGAFGTVYKGIWIPEGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVYTLLGICLTSTVQLVTQLMPYGCLLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA
```
